SpringWorks Therapeutics Inc. hopes to become the first company to win US Food and Drug Administration approval for a drug to treat desmoid tumors, a rare and potentially fatal cancer type, after a successful Phase III study of nirogacestat, and the company is already working on commercialization plans. But the drug may have a bigger opportunity as a combination treatment with cell therapy in multiple myeloma.
SpringWorks announced on 24 May that nirogacestat met the primary endpoint and was generally well tolerated in the Phase III...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

